Musculoskeletal Collaboration and Licensing Deals 2016-2024


Musculoskeletal Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2016 to 2024

Publication date
April 2024
Number of pages
Product type
Therapy profile
Report edition

Musculoskeletal Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the musculoskeletal deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of musculoskeletal deals from 2016 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of musculoskeletal dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in musculoskeletal dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the musculoskeletal field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in musculoskeletal dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of musculoskeletal deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of musculoskeletal deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in musculoskeletal deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Key benefits

Musculoskeletal Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse musculoskeletal collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Musculoskeletal Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of musculoskeletal trends and structure of deals entered into by leading biopharma companies worldwide.

Musculoskeletal Collaboration and Licensing Deals includes:

  • Trends in musculoskeletal dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of musculoskeletal deal records covering pharmaceutical and biotechnology
  • The leading musculoskeletal deals by value
  • Most active musculoskeletal licensing dealmakers

In Musculoskeletal Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Musculoskeletal Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Musculoskeletal Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse musculoskeletal collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in musculoskeletal dealmaking


2.1. Introduction

2.2. Musculoskeletal partnering over the years     

2.3. Musculoskeletal partnering by deal type

2.4. Musculoskeletal partnering by industry sector

2.5. Musculoskeletal partnering by stage of development

2.6. Musculoskeletal partnering by technology type

2.7. Musculoskeletal partnering by therapeutic indication


Chapter 3 – Financial deal terms for musculoskeletal partnering


3.1. Introduction

3.2. Disclosed financials terms for musculoskeletal partnering

3.3. Musculoskeletal partnering headline values

3.4. Musculoskeletal deal upfront payments

3.5. Musculoskeletal deal milestone payments

3.6. Musculoskeletal royalty rates


Chapter 4 – Leading musculoskeletal deals and dealmakers


4.1. Introduction

4.2. Most active in musculoskeletal partnering

4.3. List of most active dealmakers in musculoskeletal    

4.4. Top musculoskeletal deals by value


Chapter 5 – Musculoskeletal contract document directory


5.1. Introduction

5.2. Musculoskeletal partnering deals where contract document available


Chapter 6 – Musculoskeletal dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by musculoskeletal therapeutic target


Deal directory


Deal directory – Musculoskeletal deals by company A-Z 2016 to 2024

Deal directory – Musculoskeletal deals by technology type 2016 to 2024


Deal type definitions


About Biopharma Research Ltd


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: Musculoskeletal partnering since 2016

Figure 2: Musculoskeletal partnering by deal type since 2016

Figure 3: Musculoskeletal partnering by industry sector since 2016

Figure 4: Musculoskeletal partnering by stage of development since 2016

Figure 5: Musculoskeletal partnering by technology type since 2016

Figure 6: Musculoskeletal partnering by indication since 2016

Figure 7: Musculoskeletal deals with a headline value

Figure 8: Musculoskeletal deals with upfront payment values

Figure 9: Musculoskeletal deals with milestone payment

Figure 10: Musculoskeletal deals with royalty rates

Figure 11: Active musculoskeletal dealmaking activity since 2016

Figure 12: Top musculoskeletal deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3D-Side, 3SBio, 4P-Pharma, 4P Therapeutics, Abbvie, AbCellera Biologics, AC Bioscience, Accenture, Aclarion, AdventHealth, Affinia Therapeutics, AGC Asahi Glass, Ageless Biotech, AgNovos Healthcare, Akashi Therapeutics, AKL Research and Development, Alcyone Therapeutics, Aligos Therapeutics, Alkem Laboratories, Allay Therapeutics, Almirall, Alpine Immune Sciences, Altasciences, Alvogen, Alvotech, Ambry Genetics, Amend Surgical, American Association of Neuromuscular & Electrodiagnostic Medicine, Amgen, Amneal Pharmaceuticals, AMRA, AMRA Medical, Anagenesis Biotechnologies, AnaMar, Angers University, Anika Therapeutics, AnnJi Pharmaceutical, Antibe Therapeutics, Apple, Apsen Farmacutica, Aptahem, Aptorum Group, Aratana Therapeutics, Aravive Biologics, argenx, ARK Crystal, Arrowhead Pharmaceuticals, Arthrosi Therapeutics, Artialis, Asahi Kasei, AskAt, Asklepios Biopharmaceutical, Astellas Pharma, AstraZeneca, Audentes Therapeutics, Aurinia Pharmaceuticals, Autotelic BIO, Avalere Health, Avenue Therapeutics, Aveta Biomics, AveXis, Avidity Biosciences, Avion Pharmaceuticals, Axelys, Axovant Gene Therapies, Back-A-Line, Baebies, Bayer, Baylor College of Medicine, BC Platforms, Beijing Tide Pharmaceutical, Benitec Biopharma, Berg, BGI, BinnoPharm, Bio-Thera Solutions, BioCanRx, Biogen, BioGen Medical, Biohaven Pharmaceuticals, BioMarin Pharmaceutical, BioMed X Innovation Center, BiondVax, Bioqube Ventures, BioRestorative Therapies, BioSenic, Bioservo Technologies, Biosolution, Biosplice, Bioventus, BioVinc, Bison & Rose, Blueprint Medicines, Boehringer Ingelheim, Bone Biologics, Bone Therapeutics, Brain Canada, Brickell Biotech, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Caerus Strength, California Institute for Regenerative Medicine, Calimmune, Camargo Pharmaceutical Services, Can-Fite BioPharma, CANbridge Pharmaceuticals, Capricor Therapeutics, Capsigen, CareFirst BlueCross BlueShield, Carlsmed, Carna BioSciences, Cassie + Friends, Catabasis Pharmaceuticals, Catalyst Pharmaceuticals, cbdMD, Cedars-Sinai Medical Center, Celltech, Cellthera Pharma, Celltrion, Cel Sci, Centogene, Cerhum, CgBio, Changshan Pharm, Charles River Laboratories, CheckPoint Immunology, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Research Institute, Chronolife, Chugai Pharmaceutical, CHU Sainte-Justine, Cipla, CJ CheilJedang, Clementia Pharmaceuticals, CMS Medical, Coapt, Cocoon Biotech, Codiak BioSciences, Collaborative Trajectory Analysis Project, Colorado State University, Columbia University, Columbia University Medical Center, ConforMIS, Coracoid Solutions, CRISPR Therapeutics, CrystalGenomics, CSIR-Central Drug Research Institute, Cumberland Pharmaceuticals, Curasan, Cure Duchenne, CURE Pharmaceutical, CurveBeam AI, CymaBay Therapeutics, Cytoo, Cyxone, Daewoong Pharmaceutical, Dalhousie University, Defense Advanced Research Projects Agency, Delivra, Delpor, Denali Therapeutics, Department of Defense, Department of Veterans Affairs, DePuy, Distributed Bio, Duchenne UK, Duke University, Dynacure, Dyno Therapeutics, ECM Therapeutics, Ecole Polytechnique de Montreal, EGeen, Eisai, Elanco, Eli Lilly, EmergeOrtho, Emmyon, Emory University, Emovi, Endo International, Endo Ventures, Energy Medicine Research Institute, Enleofen Bio, Entrada Therapeutics, Enzene Biosciences, Equillium, Ethos Research & Development, Ethypharm, Eurofins LifeCodexx, Evonik Industries, EVOQ Therapeutics, Exagen Diagnostics, Exicure, Exonics Therapeutics, Exothera, Facio Therapies, Feinstein Institute for Medical Research, Ferring Pharmaceuticals, Fibrocell Science, Fin-ceramica faenza spa, Flexion Therapeutics, Fluidigm, Forbius, Forge Biologics, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Friends of FSH Research, FSHD Global Research Foundation, Fujifilm Kyowa Kirin Biologics, Fuji Yakuhin, Fulcrum Therapeutics, Galapagos, Galderma, Galecto, Gebro Pharma, GEn1E Lifesciences, GenEdit, GeneQuine Biotherapeutics, General Electric (GE), Genethon, Geneva Foundation, Genevant Sciences, Gennao Bio, Genome BC, Genome Canada, Genosera, George Washington University, Gero, Gilead Sciences, Graminex, Graviton Bioscience, Gravocore, Great Ormond Street Hospital (GOSH), Grunenthal, GSK, Guangzhou Ruianbo Pharmaceutical Technology, Guangzhou Ruiao Biopharmaceutical Technology, Haisco Pharmaceutical, HanAll Pharmaceuticals, Hansa Biopharma, Hanuman Pelican, HappyBond, Harbour Biomed, Harvard University, HAYA Therapeutics, HealthSnap, HealthTrio, HemoShear, Henlius Biotech, High Line Bio, Hikma Pharmaceuticals, HistoIndex, Horizon Europe, Horizon Pharma plc, Horizon Therapeutics, Hospital for Special Surgery, Howmedica Osteonics, Human Life CORD Japan, I-mab, IDIPharma, Idorsia, IGEA Clinical Biophysics, Iktos, IM-Tech, Image Analysis, ImageBiopsy Lab, Imcyse, Immunis, Impressio, In2Bones USA, Incyte, Indiana University, Innosuisse, Innovate UK, Innovent Biologics, Innovus Pharmaceuticals, Inovalon, Inserm, Integrated Biosciences, Intel, International Spine Study Group Foundation, Intrexon, Inventiva, Invibio Biomaterial Solutions, Ionis Pharmaceuticals, Ipsen, IQVIA, Ironwood Pharmaceuticals, Italfarmaco, Izana Bioscience, Jain Foundation, Janssen Research & Development, Jesse's Journey, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Tainuo, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jubilant Radiopharma, Jubilant Therapeutics, Juniper Biologics, Juvena Therapeutics, JW Pharmaceutical, Kalytera Therapeutics, Kansas State University, Karolinska Institute, Kashiv BioSciences, Kawasaki Medical School, Keck School of Medicine of USC, Kelyniam Global, Kennedy Institute of Rheumatology, KFx Medical, Kiniksa Pharmaceuticals, KiOmed Pharma, Kitov Pharma, Kolon Life Science, Kowa Pharmaceuticals America, Kuhnil Pharmaceuticals, KYE Pharmaceuticals, Laboratories Acbel, LABORATORIOS SAVAL, Laurel Venture Capital, Leadiant Biosciences, Les Laboratoires Servier, Level Brands, Levolta Pharmaceuticals, Lexicon Pharmaceuticals, LG Chem, Lima Corporate, Link Health, Locana, London School of Medicine and Dentistry, Lonza, Ludwig Institute for Cancer Research, Lupin, Lynk Pharmaceuticals, Maastricht University, Mabwell Bioscience, MainPointe, Marathon Pharmaceuticals, Marina Biotech, Maryland Stem Cell Research Fund, Massachusetts General Hospital, Massachusetts Institute of Technology, Max-Planck, Maxx Medical, Mayo Clinic, MC10, McMaster University, MDA Venture Philanthropy, Medac, Medacta, Medexus Pharmaceuticals, Mediar Therapeutics, Medicardia Health, Medidata Solutions, MedImmune, Medolife Rx, MedShape, Merck and Co, Merck KGaA, Mesoblast, Metabolon, Methuselah Foundation, Metrion Biosciences, MHC Medical Products, Microdrop, MiMedx, Miravo Healthcare, miRecule, Mithra Pharmaceuticals, Mitsubishi Tanabe Pharma, Moebius Medical, Momenta Pharmaceuticals, MoonLake Immunotherapeutics, Morphic Therapeutic, Morris Animal Foundation, MoveUP, mSKIL, MTF Biologics, Mundipharma, Muscle Activation Technique, Muscular Dystrophy Association, Musculoskeletal Transplant Foundation, Mylan Laboratories, Mylan Pharmaceuticals, Myonexus Therapeutics, MYOS, Myriad Genetics, Nanotherapeutics, National Human Genome Research Institute, National Institute of Arthritis and Musculoskeletal Diseases, National Institute on Aging, National Institutes of Health, National Science Foundation, Nationwide Children’s Hospital, Navidea Biopharmaceuticals, NeoDynamics, Nestle, Neuro42, Neurocrine Biosciences, Neuronoff, NeuroVive Pharmaceutical, NeuX Technologies, Nippon Shinyaku, Nordic Bioscience, Nordic Pharma Group, Northwell Health, Northwestern University, NovaQuest, Novartis, NT Pharma, Nuevolution, Nuritas, Nuvo Research, nView Medical, Ohio State Innovation Foundation, Ohio State University, OncoArendi Therapeutics, Oncodesign, Onkos Surgical, Open University of Israel, OPUM, Orebro University, Organon, Organovo, Orthocell, Orthofix Medical, OrthoGrid Systems, Orthopaedic Foot & Ankle Center, Ortho Regenerative Technologies, OrthoSensor, Ortoma, Osteolabs, Osteopore International, Paladin Labs, Paragon 28, Parent Project Muscular Dystrophy, Parvizi Surgical Innovation, Patient-Centered Outcomes Research Institute, Pennsylvania State University, PeptiDream, Pfenex, Pfizer, PharmaLegacy Laboratories, Pharmapark, Poietis, Precision BioSciences, Pregene Biopharma, Prevail Therapeutics, PrinterPrezz, Prometheus Laboratories, Promimic, Propella Therapeutics, PTC Therapeutics, pt Health, Purdue Pharma, Purdue Research Foundation, QuantHealth, Queen Mary University of London, Radius Health, Ramot at Tel Aviv University, Rani Therapeutics, Rebel Edibles, Recombinetics, Recursion, Regen BioPharma, Regeneron Pharmaceuticals, Regeneus, Regenstrief Institute, Regenxbio, Remedium Bio, Replicel Life Sciences, RevBio, ReveraGen BioPharma, Rheumatology Research Foundation, Ribon Therapeutics, Rigenerand, Riptide Bioscience, RMX Biopharma, Roche, Rocket Pharmaceuticals, ROMEG Therapeutics, Saint Louis University, Samsung Bioepis, Sangamo Therapeutics, Sanguine, Sanofi, Santhera Pharmaceuticals, Saphetor, Sarepta Therapeutics, Satellos Bioscience, Sayre Therapeutics, Scipher Medicine, Scribe Therapeutics, Scripps Research Institute, Scriptr Global, Second Genome, SecondWave Systems, Selecta Biosciences, Serenus.AI, Shionogi, Si-Bone, Simcere Pharmaceuticals, SimonMed Imaging, SiSaf, Sites Medical, Skyhawk Therapeutics, Smith & Nephew, Solid Biosciences, Solve GNE, SomaLogic, Sorrento Therapeutics, Southwest Research Institute, Spotlight Innovation, SQI Diagnostics, Standigm, Stempeutics, StrideBio, StrongPath, Stryker, Summit Therapeutics, Sun Pharmaceutical, Sway Medical, Swedish Bactiguard, Swedish Orphan Biovitrum, SynAct Pharma, Synpromics, Syntr Health Technologies, Tabuk Pharmaceutical, Taiwan Liposome Company, Takeda Pharmaceutical, Teijin, Teva Pharmaceuticals USA, Tevard Biosciences, Texas Christian University, The Arthritis Society, The Cyprus Institute of Neurology and Genetics, Theramex, THINK Surgical, Thuasne and Townsend Design, TissueGene, Tissue Genesis, TiumBio, TLC BioSciences, Toshiba Medical Systems Corporation, Total Joint Orthopedics, Tow Foundation, TR-Pharm, Transcenta, Transdermal Delivery Solutions, TRB Chemedica, TrialSpark, Tufts University, Turner Imaging Systems, UCB, Ultragenyx Pharmaceuticals, Unilife, United Orthopedic Group, University City Science Center, University Gottingen, University of Basel, University of Bern, University of British Columbia, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Florida, University of Illinois, University of Illinois Urbana-Champaign, University of Iowa, University of Kansas, University of Lausanne, University of Liverpool, University of L’Aquila, University of Maryland Baltimore, University of Massachusetts Medical School, University of Miami, University of Michigan, University of Minnesota, University of Missouri, University of Ottowa, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Sydney, University of Texas Southwestern Medical Center, University of Vermont, University of Verona, University of Virginia, University of Washington, University of Western Australia, Urica Therapeutics, US Army, Verily, VeriSIM Life, Vertex Pharmaceuticals, VIB, Victoria University, Virginia Commonwealth University, Virpax Pharmaceuticals, Viscogliosi Brothers, Vitalli Bio, Voronoi, Voyager Therapeutics, Wake Research Associates, Walloon Region Investment Fund, Weill Cornell Medical College, WellDyne, William Harvey Research Instutute, WishBone Medical, WuXi Biologics, Xlife Sciences, Yale University, Yposkesi, Zimmer Biomet, Zoetis

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.